GlobeNewsWire
29 May 2026, 10:50 UTC · 8h ago
Source · https://www.globenewswire.com/news-release/2026/05/29/3303489/0/en/Pharvaris-to-Present-Clinical-Data-at-the-EAACI-Annual-Congress-2026.html
Read source
Search tags
Story key points
3 claims · impact-rated
Pharvaris expects topline data from its CHAPTER-3 pivotal Phase 3 study of deucrictibant extended-release tablets in the third quarter of 2026. — Topline results from a pivotal Phase 3 study are primary value drivers for biotech stocks as they determine the likelihood of regulatory approval.
+0.60Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsules as an on-demand treatment for HAE attacks. — Preparation for submission indicates the company is moving toward commercialization, which reduces clinical risk but increases execution risk.
+0.40Pharvaris will present one oral presentation and seven flash talk/poster presentations at the EAACI Annual Congress in June 2026. — Conference presentations are routine for biopharma and typically have low immediate price impact unless unexpected data is revealed.
+0.10Ticker attribution
Continue reading
6 related stories
Model heads
The company has multiple abstracts accepted for presentation at a major medical congress, indicating positive scientific progress and visibility.
No ticker relationship head found.
Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Reuters
2h ago
